Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058832352> ?p ?o ?g. }
- W2058832352 endingPage "49" @default.
- W2058832352 startingPage "37" @default.
- W2058832352 abstract "BACKGROUND BRCA1 and BRCA2 participate in cell cycle progression, apoptosis, and DNA repair pathways. The latter role may be mediated by interaction with DNA recombinase Rad51. The purpose of this study was to evaluate the effects of genotoxic and other cytotoxic agents on expression of DNA damage-response genes (BRCA1, BRCA2, p300, and Rad51) in human prostate cancer cells. METHODS Subconfluent proliferating cultures of Tsu-Pr1 or DU-145 cells were treated with various stressful agents and assayed 24 hr later for alterations in: 1) mRNA expression (by semiquantitative reverse transcription-PCR); 2) cell viability (by trypan blue dye exclusion); and 3) protein expression (by Western blotting). RESULTS Of 26 agents screened, BRCA1 and BRCA2 mRNA reductions were observed in both cell lines after exposure to adriamycin (ADR), camptothecin (CPT), sodium selenite (SLN), and ultraviolet radiation (UV), while nitrogen mustard (HN2) caused mRNA reduction in DU-145 but not in Tsu-Pr1. Inhibition of BRCA1/2 expression by ADR and HN2 was blocked by cycloheximide, suggesting that this requires new protein synthesis, while inhibition by CPT, SLN, and UV did not require protein synthesis. Reduction of p300 and Rad51 mRNA levels occurred in parallel with that of BRCA1/2, suggesting coordinate regulation of these genes. The ability of an agent to inhibit mRNA expression was not directly correlated with cytotoxicity. ADR, CPT, UV, and SLN also caused reduction of protein levels; but the kinetics of decreases in protein vs. mRNA differed. After ADR treatment, high molecular weight (Mr hyperphosphorylated) BRCA1 decreased more rapidly than the low Mr species. BRCA2 showed a more rapid decrease in protein than mRNA, while Rad51 showed the opposite. By 48 and 72 hr post-ADR, all four mRNAs and proteins were reduced to well below control levels, except for Rad51 protein, which was only moderately decreased. CONCLUSIONS Selected DNA-damaging agents (ADR, CPT, and UV) and a reducing agent (SLN) inhibited BRCA1/2, p300, and Rad51 expression in prostate cancer cells, although decreases in mRNA vs. protein did not coincide. We postulate that temporal changes in relative protein levels affect different phases of the stress response, and that the ultimate downregulation of all four genes promotes prostate cancer survival. Prostate 40:37–49, 1999. © 1999 Wiley-Liss, Inc." @default.
- W2058832352 created "2016-06-24" @default.
- W2058832352 creator A5006540007 @default.
- W2058832352 creator A5022046028 @default.
- W2058832352 creator A5038476401 @default.
- W2058832352 creator A5041459397 @default.
- W2058832352 creator A5073642304 @default.
- W2058832352 creator A5077824760 @default.
- W2058832352 creator A5085173643 @default.
- W2058832352 creator A5091075019 @default.
- W2058832352 date "1999-06-15" @default.
- W2058832352 modified "2023-10-12" @default.
- W2058832352 title "Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells" @default.
- W2058832352 cites W1580865462 @default.
- W2058832352 cites W1611268078 @default.
- W2058832352 cites W1972710550 @default.
- W2058832352 cites W1973690102 @default.
- W2058832352 cites W1976754649 @default.
- W2058832352 cites W1977035912 @default.
- W2058832352 cites W1978943108 @default.
- W2058832352 cites W1992101827 @default.
- W2058832352 cites W2000437208 @default.
- W2058832352 cites W2004935367 @default.
- W2058832352 cites W2012300945 @default.
- W2058832352 cites W2017714068 @default.
- W2058832352 cites W2017841963 @default.
- W2058832352 cites W2019205168 @default.
- W2058832352 cites W2019431776 @default.
- W2058832352 cites W2022041752 @default.
- W2058832352 cites W2024342001 @default.
- W2058832352 cites W2024963375 @default.
- W2058832352 cites W2047460928 @default.
- W2058832352 cites W2048867718 @default.
- W2058832352 cites W2048937725 @default.
- W2058832352 cites W2053003311 @default.
- W2058832352 cites W2054519549 @default.
- W2058832352 cites W2054605948 @default.
- W2058832352 cites W2061151099 @default.
- W2058832352 cites W2066108933 @default.
- W2058832352 cites W2075417812 @default.
- W2058832352 cites W2086199722 @default.
- W2058832352 cites W2086616149 @default.
- W2058832352 cites W2091350790 @default.
- W2058832352 cites W2109465247 @default.
- W2058832352 cites W2114853255 @default.
- W2058832352 cites W2123898551 @default.
- W2058832352 cites W2153579158 @default.
- W2058832352 cites W2328105863 @default.
- W2058832352 doi "https://doi.org/10.1002/(sici)1097-0045(19990615)40:1<37::aid-pros5>3.0.co;2-p" @default.
- W2058832352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10344722" @default.
- W2058832352 hasPublicationYear "1999" @default.
- W2058832352 type Work @default.
- W2058832352 sameAs 2058832352 @default.
- W2058832352 citedByCount "28" @default.
- W2058832352 countsByYear W20588323522012 @default.
- W2058832352 countsByYear W20588323522013 @default.
- W2058832352 countsByYear W20588323522016 @default.
- W2058832352 countsByYear W20588323522017 @default.
- W2058832352 countsByYear W20588323522021 @default.
- W2058832352 crossrefType "journal-article" @default.
- W2058832352 hasAuthorship W2058832352A5006540007 @default.
- W2058832352 hasAuthorship W2058832352A5022046028 @default.
- W2058832352 hasAuthorship W2058832352A5038476401 @default.
- W2058832352 hasAuthorship W2058832352A5041459397 @default.
- W2058832352 hasAuthorship W2058832352A5073642304 @default.
- W2058832352 hasAuthorship W2058832352A5077824760 @default.
- W2058832352 hasAuthorship W2058832352A5085173643 @default.
- W2058832352 hasAuthorship W2058832352A5091075019 @default.
- W2058832352 hasConcept C104317684 @default.
- W2058832352 hasConcept C105580179 @default.
- W2058832352 hasConcept C134935766 @default.
- W2058832352 hasConcept C143425029 @default.
- W2058832352 hasConcept C150194340 @default.
- W2058832352 hasConcept C153911025 @default.
- W2058832352 hasConcept C190283241 @default.
- W2058832352 hasConcept C2778128677 @default.
- W2058832352 hasConcept C2779012473 @default.
- W2058832352 hasConcept C29537977 @default.
- W2058832352 hasConcept C3675279 @default.
- W2058832352 hasConcept C502942594 @default.
- W2058832352 hasConcept C53227056 @default.
- W2058832352 hasConcept C552990157 @default.
- W2058832352 hasConcept C55493867 @default.
- W2058832352 hasConcept C86803240 @default.
- W2058832352 hasConceptScore W2058832352C104317684 @default.
- W2058832352 hasConceptScore W2058832352C105580179 @default.
- W2058832352 hasConceptScore W2058832352C134935766 @default.
- W2058832352 hasConceptScore W2058832352C143425029 @default.
- W2058832352 hasConceptScore W2058832352C150194340 @default.
- W2058832352 hasConceptScore W2058832352C153911025 @default.
- W2058832352 hasConceptScore W2058832352C190283241 @default.
- W2058832352 hasConceptScore W2058832352C2778128677 @default.
- W2058832352 hasConceptScore W2058832352C2779012473 @default.
- W2058832352 hasConceptScore W2058832352C29537977 @default.
- W2058832352 hasConceptScore W2058832352C3675279 @default.
- W2058832352 hasConceptScore W2058832352C502942594 @default.
- W2058832352 hasConceptScore W2058832352C53227056 @default.
- W2058832352 hasConceptScore W2058832352C552990157 @default.